Please use this identifier to cite or link to this item:
|Title:||Risk of second breast cancer according to estrogen receptor status and family history||Authors:||Bouchardy, C.
Estrogen receptor status
|Issue Date:||May-2011||Citation:||Bouchardy, C., Benhamou, S., Fioretta, G., Verkooijen, H.M., Chappuis, P.O., Neyroud-Caspar, I., Castiglione, M., Vinh-Hung, V., Vlastos, G., Rapiti, E. (2011-05). Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Research and Treatment 127 (1) : 233-241. ScholarBank@NUS Repository. https://doi.org/10.1007/s10549-010-1137-z||Abstract:||A recent study reported an increased risk of contralateral estrogen-negative breast cancer after a first primary estrogen-negative breast cancer. Our study aims to confirm this result and to evaluate how the risk of second breast cancer occurrence is affected by family history of breast cancer and anti-estrogen treatment. We included all 4,152 women diagnosed with breast cancer between 1995 and 2007, using data from the population-based Geneva Cancer Registry. We compared the incidence of second breast cancer among patients according to estrogen receptor (ER) status with that expected in the general population by age-period Standardized Incidence Ratios (SIRs). Among the cohort, 63 women developed second breast cancer. Patients with ER-positive first tumors had a decreased risk of second breast cancer occurrence (SIR: 0.67, 95% CI: 0.48-0.90), whereas patients with ER-negative primary tumors had an increased risk (SIR: 1.98, 95% CI: 1.19-3.09) limited to ER-negative second tumors (SIR: 7.94, 95% CI: 3.81-14.60). Patients with positive family history had a tenfold (SIR: 9.74, 95% CI: 3.57-21.12) higher risk of ER-negative second tumor which increased to nearly 50-fold (SIR: 46.18, 95% CI: 12.58-118.22) when the first tumor was ER-negative. Treatment with anti-estrogen decreased the risk of second ER-positive tumors but not ER-negative tumors. The risk of second ER-negative breast cancer is very high after a first ER-negative tumor, in particular among women with strong family history. Surveillance and prevention of second cancer occurrence should consider both ER status of the first tumor and family history. © 2010 Springer Science+Business Media, LLC.||Source Title:||Breast Cancer Research and Treatment||URI:||http://scholarbank.nus.edu.sg/handle/10635/109626||ISSN:||01676806||DOI:||10.1007/s10549-010-1137-z|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Nov 30, 2022
WEB OF SCIENCETM
checked on Nov 30, 2022
checked on Nov 24, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.